Heading For The Exits

Space Exploration Technologies Corp. intends to raise $75 billion in the largest IPO ever, valuing the company at $1.8 trillion. This comes amid high-profile AI IPOs where insiders are cashing out, and private equity funds are facing record redemption requests. Historically high market valuations suggest that this wave of IPOs may signal a market peak. Additionally, the article mentions Bret Jensen, an analyst focused on biotech investments.

Save
Play(7min)
Comments\ \ (12)

Summary

Space Exploration Technologies Corp. is about to raise a record $75 billion at a $1.8 trillion valuation, over 90x projected 2025 revenues.
Massive AI-related IPOs and secondary offerings signal insiders cashing out amid parabolic private valuations and extreme market multiples.
Private credit and equity funds face surging redemption requests and are gating, with default rates at record highs and redemptions capped.
With markets trading at historic valuation extremes, this wave of IPOs and liquidity constraints may mark a cyclical market top.
Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More »
Sitewide Sale 2026: Get 20% Off

investment and finance concept, businessman using computer working at virtual trading graph and blurred coins in bubble on hand, stock market, profits and business growth

cherdchai chawienghong/iStock via Getty Images

On Friday, the largest IPO in global history (by capital raised) will hit the market. Space Exploration Technologies Corp. ( SPCX) will attempt to raise $75 billion at $135 per. This would value the company at roughly $1.8 trillion

This article was written by

Bret Jensen

58.05K Followers

Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Read Original at Seeking Alpha →